Video

Dr. Alam on survival differences in kidney cancer based on race and socioeconomic factors

Author(s):

Urology Times staff
Current Time 0:00
Duration 1:22
Loaded: 0%
Stream Type LIVE
Remaining Time 1:22
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Ridwan Alam, MD, a urology resident at Johns Hopkins Brady Urological Institute, discusses the abstract, “Investigation of race and associated socioeconomic factors in survival outcomes for patients with renal cell carcinoma,” which he presented at the 2022 AUA Annual Meeting (abstract PD18-12).

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
    Strategies to bridge gender disparities in AAS and citations in the oncology literature
    Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
    Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC
    Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
    Study findings highlight gender gaps in oncology authorship and citation
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
    Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
    Betty Wang, MD, discusses studies from the 2025 EAU meeting
    Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
    Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
    Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
    Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
    Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
    Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
    Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
    Related Content
    What urologists can expect in Q3 of 2025
    June 30th 2025

    What urologists can expect in Q3 of 2025

    Benjamin P. Saylor Hannah Clarke
    A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
    3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    June 6th 2025

    Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

    Hannah Clarke
    Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.
    Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
    June 5th 2025

    Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

    Hannah Clarke
    The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.
    Jad Chahoud, MD, MPH
    June 5th 2025

    Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

    Benjamin P. Saylor
    ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
    Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
    June 1st 2025

    Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

    Silas Inman
    "These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
    Subcutaneous nivolumab approved in EU, Canada for solid tumors
    May 28th 2025

    Subcutaneous nivolumab approved in EU, Canada for solid tumors

    Hannah Clarke
    The approvals are supported by findings from the phase 3 CheckMate-67T trial.
    © 2025 MJH Life Sciences

    All rights reserved.